Torrent Pharma Q4 FY26 profit drops amid JB integration

What Torrent Pharma reported for the March quarter

Torrent Pharmaceuticals Ltd reported a sharp year-on-year decline in profit for the quarter ended March 31, 2026 (Q4 FY26), with different published figures highlighting the impact of integration and exceptional costs. One report cited consolidated net profit at ₹389 crore, down 21.9% from ₹498 crore a year ago. Separately, regulatory filing-based coverage put profit after tax at ₹364 crore, down about 27% from ₹498 crore, citing exceptional items outgo. The March quarter was also described as Torrent’s first quarter after the integration of JB Pharmaceuticals following the acquisition.

Expenses jumped after JB acquisition integration

Torrent’s higher cost base was a central feature of the quarter. Expenses in the March quarter rose 37% year-on-year to ₹3,585 crore, according to the report attributing the profit decline to integration-led spending. In another set of figures, exceptional items of ₹66 crore were disclosed for the quarter. These exceptional items were described as including regulatory and statutory fees, severance pay, and other related costs associated with the JB Pharma acquisition.

Revenue growth remained strong, helped by India performance

Despite the profit pressure, revenue growth was strong in Q4 FY26. Sales for the quarter rose 41.90% year-on-year to ₹4,128 crore from ₹2,909 crore in the year-ago period. The domestic business was highlighted as a key driver, with India revenues increasing 43% to ₹2,215 crore. The growth in India was described as being led by outperformance in focus therapies and generic semaglutide performance.

Operating performance: EBITDA and margin disclosed

Torrent also reported operating profitability metrics for the quarter. Earnings before interest, tax, depreciation, and amortisation (EBITDA) stood at ₹1,356 crore, with an EBITDA margin of 32.3%. The company indicated that this EBITDA figure excludes exceptional items such as regulatory and statutory fees and severance pay, along with other acquisition-related costs tied to JB Pharma amounting to ₹66 crore.

Key numbers at a glance

JB Chemicals deal: size, structure, and timeline

The JB Chemicals & Pharmaceuticals transaction was repeatedly cited as the main context for Torrent’s quarter. Torrent completed the acquisition of 48.80% stake in JB Chemicals from KKR for ₹11,917 crore and gained controlling promoter status on Jan. 21. The company said the acquisition would enable its entry into the contract development and manufacturing organisation (CDMO) business. Another deal description called it a landmark transaction valuing JB Pharma at ₹25,689 crore on a fully diluted basis.

Transaction components disclosed in reports

Beyond the initial stake purchase, additional elements of the JB deal were outlined. Torrent purchased a 46.39% stake from Tau Investment Holdings (a KKR entity) for ₹11,917 crore, paying ₹1,600 per share. The transaction also included an open offer for 26% of public shareholding at ₹1,639.18 per share, totalling ₹6,842.8 crore. It further included the acquisition of up to 2.8% from employees at the same ₹1,600 price, costing ₹719 crore.

Debt funding, interest costs, and brokerage expectations

Ahead of results, brokerage commentary had flagged that revenue could surge due to consolidation benefits from the JB purchase, while profitability could face pressure from higher interest costs on a debt-funded acquisition. One estimate compilation said Torrent Pharma was expected to report nearly ₹578 crore consolidated net profit for the March quarter (derived from an average estimate of ₹5.78 billion), but it also highlighted wide divergence among brokerages on the profit impact. The commentary cited expectations of restructuring impact at JB and higher amortisation and interest costs, which could lead to contraction in profitability.

Full-year performance and what investors tracked

While the March quarter reflected integration and exceptional-cost pressure, full-year numbers cited in the same coverage showed growth. For the year ended March 2026, net profit rose 11.88% to ₹2,138 crore compared with ₹1,911 crore in the previous year. Investors also tracked management commentary on acquisition economics. Executives said Torrent expects to recover its investment in JB Chemicals within 2.5 years from the point of taking control, which was described as expected between January and March 2026, and that the transaction would be primarily debt-funded with a targeted cost of borrowing below 8%.

Conclusion

Torrent Pharma’s Q4 FY26 results combined strong revenue growth, especially in India, with a sharp decline in profit as expenses rose after JB integration and as exceptional acquisition-related costs were recognised. The key near-term focus remains how acquisition-led costs, interest, and restructuring items trend after Torrent gained controlling promoter status in JB Chemicals on Jan. 21.